FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.



from The Medical News http://www.news-medical.net/news/20141230/FDA-approves-Hospiras-Dyloject-(diclofenac-sodium)-Injection-for-pain-management.aspx